KY19382

KY19382 is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β, with IC50s of 19 and 10 nM, respectively. KY19382 activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β activity. KY19382 can be used for the research of high fat diet (HFD) induced metabolic diseases[1][2].

Product Specifications

CAS Number

[2226664-93-1]

Product Name Alternative

A3051

UNSPSC

12352005

Hazard Statement

H315, H319

Target

GSK-3; Wnt; β-catenin

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/ky19382.html

Purity

98.0

Solubility

DMSO : 4.17 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

O=C1NC2=C(C=C(Cl)C(Cl)=C2)/C1=C3NC4=C(C=CC=C4)C/3=N/OC

Molecular Formula

C17H11Cl2N3O2

Molecular Weight

360.19

Precautions

H315, H319

References & Citations

[1]Choi S, et, al. CXXC5 mediates growth plate senescence and is a target for enhancement of longitudinal bone growth. Life Sci Alliance. 2019 Apr 10; 2 (2) : e201800254.|[2]Choi KY, et, al. Compositions and methods for suppressing and/or treating metabolic diseases and/or a clinical condition thereof. WO2020079569.